Historical guide. This page records the UK Mounjaro shortage of early 2025 and the lessons that still apply. It is kept as background reading rather than a live supply alert. For current prices and stock, use the Mounjaro price list.
In March 2025 the UK ran short of Mounjaro (tirzepatide) at the two highest strengths, the 12.5mg and 15mg pens. Eli Lilly confirmed supply disruption, lower doses stayed largely available, and thousands of patients on the top doses were left waiting, splitting pens or dropping back a strength. Supply recovered through April and May 2025, but the episode changed how UK patients think about ordering.
What happened in 2025
Demand for tirzepatide grew faster than any weight-loss medicine before it. By early 2025 UK private prescriptions had surged, and the manufacturer could not fill the top two strengths fast enough. Patients who had titrated up to 12.5mg or 15mg over months found their usual dose out of stock at pharmacy after pharmacy, while starter doses (2.5mg to 10mg) generally remained on the shelf.
Eli Lilly prioritised existing patients and pointed to a gradual recovery from mid to late April 2025. In practice stock returned unevenly: some online pharmacies were back in supply within weeks, others took longer, and stock levels varied day to day for most of the spring.
Why it happened
- Global demand outran manufacturing. Tirzepatide was launching in new markets at the same time, and injector pen production is slow to scale.
- The top doses are where patients accumulate. Most people move up the dose ladder and stay at 12.5mg or 15mg, so those strengths carry the most demand and the least slack.
- Private UK supply is a long chain. Manufacturer, wholesaler, pharmacy, courier. A delay at any link showed up as an empty basket at checkout.
How patients coped
Three responses became common during the shortage, and each carried a lesson.
- Dropping a dose. Many prescribers moved patients from 15mg to 12.5mg, or from 12.5mg to 10mg, rather than let them go without. Appetite control softened for some but treatment continued.
- Switching pharmacy. Stock was patchy rather than absent, so patients who could move providers quickly kept going. That experience is why our switching pharmacy guide exists.
- Stretching the pen. Some people tried to eke out a pen while waiting for the next order. Our running out between pens guide covers what is and is not sensible here.
Lessons that still apply
- Order before the last dose, not after. A week of buffer turns a stock gap into an inconvenience rather than a missed dose.
- Know a second pharmacy. Keep an account and ID check ready with a backup provider so a switch takes days, not weeks.
- Talk to the prescriber early. A planned step down is far better than an unplanned break in treatment.
- Do not stockpile. Hoarding made the 2025 gap worse for people who depend on tirzepatide for type 2 diabetes, and pens have storage limits once out of the fridge.
Could it happen again?
Manufacturing capacity has grown since 2025 and the UK market has more suppliers and more pharmacies stocking every strength. Short local gaps still occur, usually at a single pharmacy rather than nationally. The best protection is the same as it was: order early, keep a backup provider, and compare stock and price across verified pharmacies rather than relying on one.
Sources
- Eli Lilly UK, manufacturer statements on tirzepatide supply, March to April 2025
- Monj pharmacy stock and price tracking across UK providers, March to May 2025
Monj is an independent price comparison index run by Medstack Ltd. We do not sell, prescribe or dispense medicines. If you cannot obtain your medication, speak to your prescriber or pharmacist.
